The US Senate Banking Committee just faced a surge of 137 amendments to the Digital Asset Market Structure Act. This flurry of legislative activity occurred rightThe US Senate Banking Committee just faced a surge of 137 amendments to the Digital Asset Market Structure Act. This flurry of legislative activity occurred right

DeepSnitch AI VS Digitap ($TAP): CLARITY Act Legislative Surge in Senate Shows DeepSnitch AI 100X Potential

The US Senate Banking Committee just faced a surge of 137 amendments to the Digital Asset Market Structure Act. This flurry of legislative activity occurred right before a 5 PM deadline on Wednesday. Traders are now scrambling to interpret how these changes will impact DeFi and stablecoin rewards.

Navigating these regulatory shifts requires more than just manual research. It requires advanced intelligence. This high-stakes environment is driving investors to compare DeepSnitch AI vs Digitap ($TAP) as they hunt for presale opportunities.

DeepSnitch AI has already raised over $1.19M in its opening stages as the presale is in Stage with a price of $0.03469 per DSNT token.

Read on to see why DeepSnitch AI is a top presale pick.

Senators submit 137 amendments to crypto bill before deadline

The markup for the Digital Asset Market Structure Act, or the CLARITY Act, is scheduled for Thursday, January 15. Senators submitted 137 amendments targeting critical areas like DeFi regulation and ethical standards for officials holding digital assets. A major standoff involves the ability of platforms to pay yield on idle stablecoin balances.

The newly released draft prohibits interest on payment stablecoins but allows rewards for staking and liquidity provision. Traditional banks are lobbying hard for these restrictions.

Coinbase CEO Brian Armstrong has called these restrictions a red line issue.

This tension shows that the regulatory landscape is shifting under the feet of retail investors.

DeepSnitch AI ($DSNT) vs Digitap ($TAP) vs Shiba Inu ($SHIB)

DeepSnitch AI

Choosing between DeepSnitch AI VS Digitap ($TAP) involves picking between different approaches to the market. While Digitap builds a financial bridge, DeepSnitch AI provides the radar.

DeepSnitch AI is a suite of blockchain surveillance tools. It solves the information asymmetry problem that leaves retail traders behind. Most people find out about whale moves or new laws after the price has already reacted. But this platform uses five specialized agents to monitor the market 24/7.

Four of these agents are now live for presale participants to test. The most significant tool is AuditSnitch. It allows you to paste a contract address and receive an instant verdict. The system labels tokens as CLEAN, CAUTION, or SKETCHY.

SnitchFeed acts as the primary monitoring system. It tracks Dominance Surges and sentiment flips on social channels. This allows you to catch whale splashes before they trend. The project also features SnitchGPT.

This assistant simplifies on-chain chaos into clear answers within Telegram. You can ask for the risk score of a trending token and get a plain explanation.

The presale has already seen significant growth. It started at $0.0151 and has now hit $0.03469. With only about 2 weeks left until the official launch, the window to secure these prices is closing.

Digitap

Digitap is a financial interface between digital assets and traditional banking systems. It enables users to spend crypto directly through Visa-supported merchants. This approach solves a long-standing limitation in the crypto space regarding asset conversion. The platform operates a live mobile app that integrates wallet management and fiat compatibility.

The DeepSnitch AI vs Digitap comparison reveals that both projects prioritize real-world function. Analysts have noted that Digitap targets vast segments like global remittances and underbanked users. DeepSnitch AI vs Digitap is essentially an AI analytics vs trading platform comparison.

Shiba Inu

Shiba Inu was priced around $0.0000088 on January 14th. SHIB pulled back after the 7% rebound from the 50-day EMA at $0.00000838. The meme coin has been struggling at the $0.00000924 resistance level since last November. If SHIB passes this level, analysts say it could target the 200-day EMA at $0.00001049.

But if support breaks at $0.00000838, the token could fall toward $0.00000755.

Bottom line

The legislative chaos in the Senate proves that crypto regulations can change in a single day. DeepSnitch AI gives you the surveillance tools to outsmart whales and navigate regulatory uncertainty.

It has already raised $1.19M, and the Stage 4 window is closing fast. This is your last chance to secure tokens at $0.03469 before the mystery announcement hits the public.

For more information, visit the official website, and follow X and Telegram.

FAQ

Is DeepSnitch AI better than Digitap for tracking regulations?

Yes. DeepSnitch AI scans for events like regulatory shifts and impacts on specific protocols in real time.

Can I use DeepSnitch AI to find Shiba Inu breakouts?

DeepSnitch AI uses SnitchFeed to track Dominance Surges and sentiment flips, helping you spot the next SHIB pump before the herd notices.

What is the better choice when comparing Deepsnitch AI ($DSNT) vs Digitap ($TAP)?

DeepSnitch AI is the premier choice because it provides live utility through four active agents and a 100x growth narrative heading into its launch.

The post DeepSnitch AI VS Digitap ($TAP): CLARITY Act Legislative Surge in Senate Shows DeepSnitch AI 100X Potential appeared first on Blockonomi.

Market Opportunity
The AI Prophecy Logo
The AI Prophecy Price(ACT)
$0,02587
$0,02587$0,02587
-%1,56
USD
The AI Prophecy (ACT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26